24.99  -2.905 (-10.41%)		01-30 16:00
Open: 27.22 High: 27.6605 Volume: 289,392		Pre. Close: 27.895 Low: 24.31 Market Cap: 12,357(M)

Short term
Mid term
Targets	6-month :	58.64	1-year :	80.59
Resists	First :	50.2	Second :	69
Pivot price	31.32
Supports	First :	19.8	Second :	16.47
MAs	MA(5) :	29.28	MA(20) :	32.24
	MA(100) :	19.22	MA(250) :	13.49
MACD	MACD :	1.1	Signal :	2.2
%K %D	K(14,3) :	17.4	D(3) :	19.8
RSI	RSI(14): 46.5
52-week	High :	83.59	Low :	0.09

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RGC ] has closed above bottom band by 25.0%. Bollinger Bands are 129.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 36 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	27.67 - 27.86	27.86 - 28.01
Low:	23.99 - 24.15	24.15 - 24.29
Close:	24.75 - 25.02	25.02 - 25.24

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Sat, 31 Jan 2026
Regencell Bioscience Holdings Limited (NASDAQ:RGC) Short Interest Down 28.1% in January - MarketBeat

Fri, 30 Jan 2026
A Look At Regencell Bioscience Holdings (RGC) Valuation After Market Value Surges Despite Ongoing Challenges - Sahm

Wed, 28 Jan 2026
Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.4% - Here's What Happened - MarketBeat

Tue, 27 Jan 2026
Regencell Bioscience Holdings (RGC) Is Up 6.5% After Valuation Surges Despite DOJ Probe And No Revenue - simplywall.st

Tue, 27 Jan 2026
Regencell Bioscience Holdings (RGC) Is Up 6.5% After Valuation Surges Despite DOJ Probe And No Revenue - Sahm

Tue, 13 Jan 2026
U.S. Markets Declined Tuesday; Regencell Bioscience Took Biggest Hit - Barron's

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	494 (M)
Shares Float	18 (M)
Held by Insiders	88.5 (%)
Held by Institutions	0.1 (%)
Shares Short	1,290 (K)
Shares Short P.Month	1,180 (K)

EPS	-0.01
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-33.3 %
Return on Equity (ttm)	-54.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.01
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-2499
PEG Ratio	0
Price to Book value	2499
Price to Sales	0
Price to Cash Flow	-3973.41

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.